Pharmacology & Toxicology Research
https://acadpub.com/ptr

Gouty Arthritis: Pathophysiology, Current Therapeutic Strategies and the Emerging Role of Artificial Intelligence

Ch. Shrivalli and P. Veeresh Babu

Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Hyderabad 500090, Telangana, India

About the Article

Open Access

Review Article

DOI: 10.68163/ptr.2026.79

How to Cite:
Shrivalli C, Babu PV. Gouty arthritis: Pathophysiology, current therapeutic strategies and the emerging role of artificial intelligence, *Pharmacol Toxicol Res.* 2026;2:76-84.

Keywords:
Artificial intelligence, gouty arthritis, hyperuricemia, inflammation, monosodium urate crystals, urate-lowering therapy

Corresponding author:
P. Veeresh Babu,
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Hyderabad 500090, Telangana, India

© The Authors, 2026. Published by the Academia Publications. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (CC-BY) 4.0. (http://creativecommons.org/licenses/by/4.0)

ABSTRACT

Gouty arthritis is a chronic inflammatory metabolic disorder that is one of the most prevalent forms of inflammatory arthritis worldwide and its burden continues to increase due to various factors, including obesity, dietary changes, sedentary lifestyles and metabolic disorders. Persistent hyperuricemia promotes the deposition of monosodium urate (MSU) crystals, which triggers acute gout flares and may progress to chronic tophaceous gout, accompanied by irreversible joint damage and disability. The pathogenesis involves activation of innate immune pathways and the NLRP3 inflammasome, resulting in the release of pro-inflammatory cytokines. The condition can be diagnosed by assessing serum urate levels, clinical manifestations and, when appropriate, MSU crystal deposition, while management includes pharmacological treatment and lifestyle modification. Emerging targeted therapies and artificial intelligence are expected to improve long-term disease monitoring, enhance clinical outcomes and reduce the global burden of gout.

INTRODUCTION

Definition: Gouty arthritis is a chronic disease characterized by the deposition of monosodium urate (MSU) crystals in synovial joints and periarticular tissues as a consequence of chronic hyperuricemia[1,2]. When serum urate concentrations exceed the saturation threshold, urate crystals can form and activate innate immune pathways, particularly the NLRP3 inflammasome, resulting in the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), which contributes to acute inflammatory attacks[3-5]. Clinically, gout is characterized by recurrent episodes of acute monoarthritis accompanied by intense pain, redness, swelling and reduced mobility, most commonly affecting the first metatarsophalangeal joint[6,7]. If left untreated, recurrent flares can lead to irreversible joint damage and progression to chronic tophaceous gout, resulting in functional impairment and reduced quality of life[8]. Beyond its articular manifestations, gout is increasingly recognized as a systemic metabolic inflammatory disease associated with comorbid conditions such as obesity, chronic kidney disease, cardiovascular disease and type 2 diabetes mellitus[8,9].

Epidemiology and global disease burden: Gout is one of the most prevalent inflammatory diseases worldwide, with its prevalence varying according to factors such as geographic region, ethnicity, age and sex[7,10]. Recent epidemiological studies have indicated a steady increase in the global burden of gout over the past three decades[11,12]. The highest prevalence has been reported in developed countries and among Pacific Island populations and gout is more commonly observed in men than in women. Consequently, gout represents a substantial public health burden through its effects on quality of life and healthcare utilization, emphasizing the need for effective preventive and therapeutic strategies[8].

Geographic trends: The prevalence of gout is increasing worldwide, with marked geographical variations in its incidence and disease burden due to factors such as

ACADEMIA Publications

genetic susceptibility, lifestyle, dietary habits and access to healthcare[7,10]. A substantial disease burden has been reported in developed countries, including the United States, Canada, Australia and New Zealand, where genetic predisposition and comorbidities contribute to disease development[10]. In Europe, population aging and the increasing prevalence of metabolic disorders have contributed to the growing number of gout cases. In other parts of the world, including several Asian countries such as China, Japan and South Korea, rapid urbanization, Westernized dietary habits and sedentary lifestyles have contributed to a steady increase in disease prevalence. Regions such as Africa and Latin America have relatively lower reported prevalence; however, changes in lifestyle and dietary patterns may contribute to an increasing disease burden in these regions. These global trends emphasize the combined influence of genetic, metabolic, environmental and socioeconomic factors on the epidemiology of gout. Significant geographical variation in the epidemiology of gout across continents is illustrated in Fig. 1.

Comorbidities with gout: Gout commonly coexists with several metabolic and cardiovascular disorders[8]. Metabolic syndrome, cardiovascular disease, Chronic Kidney Disease (CKD), obesity and type 2 diabetes mellitus are among the most common comorbidities[9,13]. Among these, obesity and metabolic syndrome play important roles, as increased adiposity may contribute to hyperuricemia through increased urate production and reduced renal urate excretion. CKD is another important factor in the pathogenesis of gout because impaired renal function reduces urate clearance, thereby promoting hyperuricemia and subsequent MSU crystal deposition in joints[9]. Gout is also strongly associated with cardiovascular disease and has been linked to an increased risk of hypertension, coronary artery disease, stroke and heart failure, contributing to increased morbidity and mortality[13]. Other associated disorders, such as nephrolithiasis, dyslipidemia and gastrointestinal disorders, further demonstrate that gout is a systemic disease extending beyond joint inflammation. Overall, gout should be considered a systemic inflammatory-metabolic disease rather than solely a joint disease[8,13,14].

Etiology and risk factors: Persistent hyperuricemia resulting from either overproduction of uric acid or impaired renal urate excretion is one of the major underlying causes of gouty arthritis. Dietary and lifestyle factors also play crucial roles in disease development and progression. Therefore, attention should be given to the consumption of purine-rich foods, including red meat and shellfish, as well as alcohol and fructose-sweetened beverages[3]. Additional risk factors include obesity and metabolic syndrome, which may impair urate excretion and renal clearance. Furthermore, there is a close bidirectional relationship between hyperuricemia and CKD, whereby impaired renal function reduces urate clearance, while hyperuricemia may contribute to renal injury. This interaction can promote MSU crystal deposition and contribute to the progression of gouty arthritis[15-17].

Clinical manifestations: Acute gout flares usually develop abruptly, often during nighttime or in the early morning. The characteristic feature is severe joint pain, which typically begins at night or in the early morning and reaches its peak intensity within 12-24 hrs. The pain is often accompanied by erythema, swelling, warmth, tenderness and reduced joint




Fig. 1: Geographical distribution of gouty arthritis

The boundaries, names and designations shown on this map do not imply endorsement or acceptance by Pharmacology and Toxicology Research or its publisher of any territorial or jurisdictional claims




Fig. 2: Clinical symptoms of Gouty arthritis

mobility. The first metatarsophalangeal joint, a manifestation known as podagra, is the most commonly affected site, although other joints, including the ankle, knee, wrist and elbow, may also be involved[6,7,14]. The clinical manifestations are illustrated in Fig. 2.

Recurrent acute flares may result in persistent joint pain and stiffness, impaired mobility and progressive joint dysfunction[6,8]. As the disease progresses to an advanced stage, prolonged hyperuricemia can lead to the development of tophi, which are nodular deposits of MSU crystals within joints and soft tissues that can cause joint deformation and chronic pain[6,7]. Acute attacks may also be accompanied by systemic symptoms, including fatigue, malaise and low-grade fever[6,7]. Early diagnosis and appropriate treatment are essential for preventing recurrent gout flares, chronic tophaceous gout and irreversible joint damage[6,8].

Molecular pathophysiology of gout: The molecular pathogenesis of gouty arthritis can be broadly described in four stages: Persistent hyperuricemia, formation and deposition of MSU crystals, acute inflammatory flares and chronic gout with tophus formation, which may ultimately result in joint damage and deformity[18]. MSU crystals trigger inflammation by initiating an inflammatory cascade involving the activation of immune cells and complement pathways, as well as cellular injury and apoptosis[4,19,20]. Following phagocytic uptake of MSU crystals by macrophages and synoviocytes, MSU crystals activate the NLRP3 inflammasome, leading to the production and release of inflammatory mediators, particularly IL-1β, as well as other mediators including tumor necrosis factor-α (TNF-α), prostaglandins and leukotriene B4. These mediators contribute to the recruitment and activation of mononuclear and polymorphonuclear leukocytes[21].

IL-1β-mediated signaling is a key driver of acute gout inflammation[1]. Neutrophil Extracellular Traps (NETs) can contribute to both the propagation and resolution of inflammation by modulating cytokine activity and facilitating the aggregation and sequestration of MSU crystals[4]. The stepwise molecular pathogenesis of gout is illustrated in Fig. 3.

Disease progression and complications:

- **Persistent hyperuricemia:** Chronic hyperuricemia promotes the accumulation and deposition of MSU crystals within the joints and periarticular tissues, resulting in recurrent inflammation and progressive structural damage
- **Tophi formation:** Tophi are granuloma-like structures composed primarily of MSU crystals surrounded by inflammatory cells and connective tissue[1]. These deposits commonly occur in joints, tendons, cartilage and other soft tissues[6]. Their progressive accumulation may cause chronic pain, joint deformity and functional impairment, ultimately contributing to osteoarticular destruction[22,23]
- **Joint degeneration:** Persistent inflammation and MSU crystal deposition promote joint degeneration, characterized by chronic synovitis and bone erosion, which may ultimately result in irreversible joint destruction and disability[1,22,23]
- **Clinical significance:** Early diagnosis and appropriate urate-lowering therapy aimed at maintaining serum urate concentrations under control are important for preventing disease progression and minimizing complications[8]

Treatment of gout: Management of gouty arthritis requires a multidisciplinary approach aimed at controlling acute inflammation, lowering serum urate concentrations and preventing recurrent flares, thereby minimizing long-term complications. Treatment includes management of acute episodes, long-term urate-lowering therapy, flare prophylaxis, lifestyle modifications and management of comorbidities[24-26].




Fig. 3: Mechanistic overview of gouty arthritis development and progression

Treatment of acute gout flares: Acute gout attacks are characterized by the rapid development of severe pain, swelling, erythema and reduced functional capacity, primarily resulting from inflammation induced by MSU crystals. Treatment aims to rapidly relieve pain and suppress inflammation[24].

- **NSAIDs:** Commonly prescribed NSAIDs include indomethacin, naproxen and diclofenac. These agents reduce pain and inflammation primarily through inhibition of cyclooxygenase (COX) enzymes. However, caution is required when prescribing NSAIDs to patients with gastrointestinal, renal, or cardiovascular disease[24,25].
- **Colchicine:** Colchicine inhibits microtubule polymerization, thereby reducing neutrophil activation, migration and inflammatory responses. Dose-related gastrointestinal adverse effects are a major reason that low-dose regimens are preferred over high-dose regimens[24,27]
- **Corticosteroids:** Corticosteroids may be prescribed when NSAIDs or colchicine are contraindicated or unsuitable. They are available in oral, intra-articular and intramuscular formulations and suppress inflammation through multiple mechanisms, including inhibition of cytokine production and immune-cell activation[24,28].
- **Interleukin-1β inhibitors for severe or refractory acute gout:** MSU crystal-induced activation of the NLRP3 inflammasome promotes the production of IL-1β, which contributes to neutrophil recruitment and amplification of the inflammatory response. Biologic agents targeting the IL-1 pathway, including anakinra and canakinumab, have demonstrated efficacy in selected patients with severe or refractory gout when conventional therapies are ineffective or contraindicated[29]

Long-term urate-lowering therapy: Although, acute treatment is used primarily to control inflammation and relieve symptoms, long-term management focuses on maintaining serum urate concentrations below the recommended target, commonly <6 mg/dL. Sustained reduction in serum urate promotes the dissolution of previously formed urate crystals and prevents the formation and deposition of new crystals[24].

Xanthine oxidase inhibitors: Xanthine oxidase inhibitors reduce uric acid production by inhibiting xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid. They are commonly used as first-line agents for long-term urate-lowering treatment.

- **Allopurinol:** Allopurinol is one of the most frequently prescribed medications for reducing serum urate concentrations and has long been a cornerstone of chronic gout management. It inhibits xanthine oxidase, thereby reducing the conversion of hypoxanthine and xanthine to uric acid[24]
- **Febuxostat:** Febuxostat is a non-purine, selective xanthine oxidase inhibitor that inhibits the enzyme in both its oxidized and reduced forms. It is effective for lowering serum urate concentrations in patients who have an inadequate response to, or cannot tolerate, allopurinol[30].




Fig. 4: Classification of pharmacological agents used in the treatment of acute and chronic gouty arthritis

- **Uricosuric agents:** Patients with underexcretion of urate or those who are intolerant of xanthine oxidase inhibitors may be treated with uricosuric agents, which increase renal urate excretion by reducing tubular urate reabsorption.
- **Probenecid:** Probenecid increases urinary urate excretion primarily by inhibiting the URAT1 transporter in the proximal renal tubules, thereby reducing renal tubular reabsorption of urate[24]

Treatment for refractory or severe gout: More aggressive treatment may be necessary for patients with severe or refractory gout, particularly those with persistent hyperuricemia and extensive or progressive tophaceous disease.

- **Pegloticase:** Pegloticase is a PEGylated recombinant uricase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble metabolite that can be readily eliminated through the urine. Because humans lack functional endogenous uricase, pegloticase provides an alternative metabolic pathway for uric acid degradation[31]. It is indicated for patients with severe chronic gout who have not achieved adequate control with conventional urate-lowering therapies. The classification of pharmacological treatments for gout is presented in Fig. 3.

Non-pharmacological therapy and preventive measures: Lifestyle modifications, including dietary modification and regular physical activity, are important components of gout management alongside pharmacological therapy. Foods rich in purines, including red meat, organ meats and certain shellfish, should be limited, while dietary patterns emphasizing low-fat dairy products, vegetables and adequate fluid intake may be encouraged[25,26,32]. Regular physical activity and weight reduction may help improve serum urate control and reduce the frequency of gout flares. Continuous monitoring and effective management of comorbid conditions, including obesity, hypertension and CKD, are also important components of comprehensive gout management[24-26]. Figure 4 presents the classification of pharmacological agents used in the treatment of acute and chronic gouty arthritis.

Future perspectives and new therapeutic approaches: Future therapeutic strategies focus on developing safer and more targeted alternatives to regulate urate metabolism and inflammatory pathways. Novel agents, such as the selective URAT1 inhibitor dotinurad, have demonstrated effective reductions in serum urate concentrations with a favorable safety profile in patients with gout. Similarly, the investigational agent verinurad, particularly when used in combination with xanthine oxidase inhibitors, has shown promising urate-lowering effects. Selective NLRP3 inflammasome inhibitors, such as dapansutrile (OLT1177), are also emerging as potential therapeutic candidates that target IL-1β-mediated inflammation. Furthermore, precision medicine and pharmacogenomics may facilitate individualized treatment approaches, potentially minimizing adverse drug reactions and improving clinical outcomes during long-term therapy[33-36].

Emerging role of artificial intelligence in gouty arthritis management: Artificial intelligence (AI) has increasingly influenced the diagnosis, prognosis and management of

Table 1: Alternatives and complementary treatment

Plant Name	Extraction	Experiment Model	Observations	Conclusion	References
Eucalyptus torquata L. (Flowers).	Methanol extraction; HPLC-PDA-MS/MS analysis.	*In vitro*: XO inhibition assay, COX-1/COX-2 inhibition assay, 5-LOX inhibition, hyaluronidase inhibition, albumin denaturation, membrane stabilization, histamine release, protease inhibition assays; DPPH, ABTS, FRAP antioxidant assays.	Potent inhibition of XO, COX-1, COX-2, 5-LOX; excellent COX-2 selectivity; 46 metabolites identified including phloroglucinols, gallic and ellagic acid derivatives, flavonoids.	Methanolic flower extract demonstrated significant anti-gouty arthritis potential via multi-enzyme inhibition.	Ashour *et al.*[37]
Barringtonia racemosa L. (Inflorescence axes, Leaves, Pericarps, Endosperms).	Methanol extraction; Folin-Ciocalteu assay for TPC.	*In vitro*: XO inhibition assay (spectrophotometric at 295 nm); Albumin denaturation inhibition assay; Folin-Ciocalteu TPC assay; Oxypurinol as positive control.	Inflorescence axes extract showed highest XO inhibition (59.54%) at 0.1% w/v; albumin denaturation inhibition 70.58%; leaves had highest TPC (53.94 mg GAE/g DW).	Verified *In vitro* anti-inflammatory and XO inhibitory activity supporting use in alleviating gouty arthritis.	Osman *et al.*[38]
Sparattosperma leucanthum (Vell.) K. Schum (Leaves).	Ethyl acetate (SLE), methanol (SLM) and aqueous (SLW) extractions.	*In vitro*: XO inhibition assay; In vivo: Potassium oxonate-induced hyperuricemia in mice; MSU crystal-induced paw edema model (anti-inflammatory); hepatic XOD inhibition measured.	SLW at 125 mg/kg reduced hyperuricemia; SLE inhibited XO *In vitro* at 100 µg/mL; SLE and SLW exhibited marked anti-inflammatory effects in a paw edema model.	Ethyl acetate, methanol and aqueous extracts demonstrated marked an555ti-hyperuricemic and anti-gouty arthritis activity.	Lima *et al.*,[39]
Cistus riticus L. and *Plantago ciliata* Desf. (Whole plant).	Acetonic and aqueous solvent extractions; UHPLC-MS/MS analysis.	*In vitro*: XO inhibition assay; Uric acid dissolution power assay; Total phenol, flavonoid, tannin quantification; Haemolytic effect on human erythrocytes.	Acetonic extracts showed most significant XO inhibition; aqueous extracts showed highest uric acid dissolution (>450 mg/L); 19 phenolic compounds identified; no toxic effect on RBCs.	Extracts demonstrated *In vitro* XO inhibitory and uric acid dissolution activity with safe haemolytic profile.	Bouakkaz *et al.*[40]
Artemisia vulgaris L. (Aerial parts).	96% ethanol extraction; fractionated into hexane, ethyl acetate and methanol fractions.	*In vitro*: XO inhibition assay; DPPH and ROS scavenging assays; In silico: Molecular docking and pharmacokinetics (ADMET) of isolated compounds.	Ethyl acetate fraction showed most potent XO inhibition and ROS suppression; kaempferol and artemisinin showed strong XO inhibitory activity comparable to allopurinol.	Ethyl acetate fraction supports development as a safe anti-gout phototherapeutic agent.	Trinh *et al.*[41]




Fig. 5: Role of AI in management of gouty arthritis

gouty arthritis by enabling data-driven clinical decision-making. Machine learning and deep learning algorithms can integrate clinical, biochemical and genetic data to facilitate early diagnosis and assessment of disease progression. AI-assisted ultrasonography and Dual-energy Computed Tomography (DECT) have the potential to improve the detection of MSU crystal deposition and assessment of disease burden. Furthermore, AI-based approaches may facilitate individualized treatment strategies by incorporating patient-specific characteristics and treatment histories. AI may also accelerate the identification and development of novel therapeutic targets and treatment agents. Despite these promising applications, further validation is required to establish their clinical utility and support widespread implementation[36]. The potential role of AI in gouty arthritis management is further illustrated in Fig. 5.

CONCLUSION

Gouty arthritis is a chronic inflammatory disease characterized by the deposition of MSU crystals resulting from persistent hyperuricemia. Effective long-term management requires both pharmacological and non-pharmacological approaches to control serum urate concentrations, prevent recurrent flares and minimize disease-related complications. Recent advances in targeted therapies, individualized treatment approaches and artificial intelligence have the potential to improve disease diagnosis, monitoring and management. Continued advances in these areas may contribute to improved patient outcomes and a reduction in the global burden of gout.

ACKNOWLEDGMENT

The authors express their sincere gratitude to their institution and academic mentors for their continuous encouragement, valuable guidance and unwavering support throughout the preparation of this review manuscript. The authors also acknowledge the contributions of researchers and scientific communities whose published works have provided substantial insights into the understanding of gouty arthritis, its pathophysiology, therapeutic strategies and the emerging applications of artificial intelligence in disease management. Their collective contributions have significantly enriched the scientific foundation of this review.

REFERENCES

1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. *Lancet.* 2021;397(10287):1843-1855.
2. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol.* 2020;16(7):380-390.

3. Yang S, Liu H, Fang XM, Yan F, Zhang Y. Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions. *Int Immunopharmacol*. 2024;132:111932. 10.1016/j.intimp.2024.111932
4. Li C, Wu C, Li F, et al. Targeting neutrophil extracellular traps in gouty arthritis: insights into pathogenesis and therapeutic potential. *J Inflamm Res*. 2024;17:1735-1763
5. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. *Nat Rev Rheumatol*. 2017;13(11):639-647.
6. Menon SG, Rednam M, Gujarathi R, Maher L. Gout. In: *StatPearls*. StatPearls Publishing; 2026. Updated April 12, 2026. Accessed November 2, 2026. https://www.ncbi.nlm.nih.gov/books/NBK546606/
7. Asghari KM, Zahmatyar M, Seyedi F, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. *BMC Musculoskelet Disord*. 2024;25(1):1047. doi:10.1186/s12891-024-08180-9
8. Timsans J, Palomäki A, Kauppi M. Gout and hyperuricemia: a narrative review of their comorbidities and clinical implications. *J Clin Med*. 2024;13(24):7616. doi:10.3390/jcm13247616
9. Jeong H, Chang YS, Jeon CH. Gout comorbidities: results from the Korean National Health and Nutrition Examination Survey. *Adv Rheumatol*. 2024;64(1):76. doi:10.1186/s42358-024-00413-8
10. GBD 2021 Gout Collaborators. Global, regional and national burden of gout, 1990-2020 and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol*. 2024;6(8):e507-e517. doi:10.1016/s2665-9913(24)00117-6
11. Jin S, Wang Y, Yan S, et al. Global burden and trends of gout incidence and prevalence. *Chin Med J (Engl)*. 2025;138(23):3153-3162.
12. Tang X, Deng D, Wu Q. Global, regional and national burden of gout among older adults (≥65) from 1990 to 2021 and projections for 2050. *Front Public Health*. 2025;13:1540190. doi:10.3389/fpubh.2025.1540190
13. Oka P, Chong WM, Ng DX, Aau WK, Tan NC. Epidemiology and risk factors associated with gout control among adult Asians: a real-world retrospective cohort study. *Front Med (Lausanne)*. 2023;10:1253839. doi:10.3389/fmed.2023.1253839
14. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective - a review. *J Adv Res*. 2017;8(5):495-511.
15. Casanova AG, Morales AI, Vicente-Vicente L, López-Hernández FJ. Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis. *Front Pharmacol*. 2024;15:1373258. doi:10.3389/fphar.2024.1373258
16. Johnson RJ, Sanchez Lozada LG, Lanaspa MA, Piani F, Borghi C. Uric acid and chronic kidney disease: still more to do. *Kidney Int Rep*. 2023;8(2):229-239.
17. Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy. *Diagnostics (Basel)*. 2021;11(9):1674. doi:10.3390/diagnostics11091674
18. Hosseinikhah SM, Barani M, Rahdar A, et al. Nanomaterials for the diagnosis and treatment of inflammatory arthritis. *Int J Mol Sci*. 2021;22(6):3092. doi:10.3390/ijms22063092
19. Wessig AK, Hoffmeister L, Klingberg A, et al. Natural antibodies and CRP drive anaphylatoxin production by urate crystals. *Sci Rep*. 2022;12(1):4483. doi:10.1038/s41598-022-08311-z
20. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. *Arthritis Res Ther*. 2006;8(suppl 1):S3. doi:10.1186/ar1908
21. Li D, Yuan S, Deng Y, et al. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. *Front Immunol*. 2023;14:1282890. doi:10.3389/fimmu.2023.1282890
22. Ji Z, Huang Y, Liang L, et al. Clinical characteristics and risk factors associated with bone erosion in patients with tophi. *Adv Rheumatol*. 2024;64(1):18. doi:10.1186/s42358-023-00336-w
23. Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatol*. 2015;67(10):2557-2568. doi:10.1002/art.39254
24. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760.
25. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2017;76(1):29-42.
26. Conley B, Bunzli S, Bullen J, et al. What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines. *BMC Rheumatol*. 2023;7(1):15.
27. Terkeltaub RA. Colchicine update: 2008. *Semin Arthritis Rheum*. 2009;38(6):411-419.
28. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*. 2012;64(10):1431-1446.
29. Schlesinger N, Pillinger MH, Simon LS, Lipsky PE. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review. *Arthritis Res Ther*. 2023;25(1):128. doi:10.1186/s13075-023-03098-4
30. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med*. 2005;353(23):2450-2461.

31. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. *JAMA*. 2011;306(7):711-720.
32. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake and the risk of gout in men. *N Engl J Med*. 2004;350(11):1093-1103.
33. Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. *Clin Exp Nephrol*. 2020;24(suppl 1):53-61.
34. Tan PK, Liu S, Gunic E, Miner JN. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. *Sci Rep*. 2017;7(1):665.
35. Marchetti C, Swartzwelter B, Gamboni F, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. *Proc Natl Acad Sci USA*. 2018;115(7):E1530-E1539. doi:10.1073/pnas.1716095115
36. Punzi L, Scagnellato L, Galozzi P, et al. Gout: one year in review 2025. *Clin Exp Rheumatol*. 2025;43(5):799-808.
37. Ashour RMS, El-Shiekh RA, Sobeh M, Abdelfattah MAO, Abdel-Aziz MM, Okba MM. *Eucalyptus torquata* L. flowers: a comprehensive study reporting their metabolites profiling and anti-gouty arthritis potential. *Sci Rep*. 2023;13(1):18682. doi:10.1038/s41598-023-45499-0
38. Osman NI, Sidik NJ, Awal A, Adam NAM, Rezali NI. In vitro xanthine oxidase (XO) and albumin denaturation inhibition assay of *Barringtonia racemosa* L. and total phenolic content analysis for potential anti-inflammatory use in gouty arthritis. *J Intercult Ethnopharmacol*. 2016;5(4):343-349.
39. Lemos Lima RC, Ferrari FC, de Souza MR, de Sá Pereira BM, de Paula CA, Saúde-Guimarães DA. Effects of extracts of leaves from *Sparattosperma leucanthum* on hyperuricemia and gouty arthritis. *J Ethnopharmacol*. 2015;161:194-199.
40. Bouakkaz H, Djeridane A, Mahfoudi R, et al. Xanthine oxidase inhibitory activity and uric acid dissolution power of some plant extracts: in vitro therapeutical approach for gout treatment. *Rev Bras Farmacogn*. 2024;34(6):1340-1352.
41. Trinh PTN, Truc NC, Danh TT, et al. A study on the antioxidant, anti-inflammatory and xanthine oxidase inhibitory activity of the *Artemisia vulgaris* L. extract and its fractions. *J Ethnopharmacol*. 2024;334:118519. doi:10.1016/j.jep.2024.118519